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INTRODUCTION 
 
The trends toward an increased aged population (the 
proportion of individuals aged 65 years and over) is a 
major public health problem, especially in China [1, 2]. 
Worldwide, the estimated number of elderly population 
was 962 million in 2017, and the growing rate was 
approximately 3% per year [3]. China has the largest 
elderly population in the world, with more than 225 
million elderly people. The number of elderly people in  
 
China is projected to be 400 million by 2030 [4]. 
Ageing is a complex process characterized by 
progressive degradation of structural and functional 
integrity, during which the ability to maintain 
homeostasis is gradually lost, leading to the risk of 
impaired function and disease susceptibility [5–8]. 
Furthermore, ageing is a major risk factor for various 
chronic diseases [8]. However, there is great 
heterogeneity in health outcomes among elderly 
individuals of the same age group, suggesting that 
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ABSTRACT 
 
Age-related disease burdens increased over time, and whether plasma peptides can be used to accurately 
predict age in order to explain the variation in biological indicators remains inadequately understood. Here we 
first developed a biological age model based on plasma peptides in 1890 Chinese Han adults. Based on mass 
spectrometry, 84 peptides were detected with masses in the range of 0.6-10.0 kDa, and 13 of these peptides 
were identified as known amino acid sequences. Five of these thirteen plasma peptides, including fragments of 
apolipoprotein A-I (m/z 2883.99), fibrinogen alpha chain (m/z 3060.13), complement C3 (m/z 2190.59), 
complement C4-A (m/z 1898.21), and breast cancer type 2 susceptibility protein (m/z 1607.84) were finally 
included in the final model by performing a multivariate linear regression with stepwise selection. This 
biological age model accounted for 72.3% of the variation in chronological age. Furthermore, the linear 
correlation between the actual age and biological age was 0.851 (95% confidence interval: 0.836-0.864) and 
0.842 (95% confidence interval: 0.810-0.869) in the training and validation sets, respectively. The biological age 
based on plasma peptides has potential positive effects on primary prevention, and its biological meaning 
warrants further investigation. 
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actual age is not an optimal indicator of the ageing 
progress [9]. 
 
Actual age correlates with the accumulation of 
biological changes, and individuals with the same actual 
age undergo these changes at different rates [10]. 
Biological age is used to measure damage accumulation 
with age at an individual level and can be quantified 
from the known biomarkers of ageing [11, 12]. To date, 
the ageing biomarkers include telomere length [13], 
DNA methylation [14–16], transcriptomic predictor [17, 
18], plasma peptide [19], IgG N-glycosylation [20, 21], 
facial morphology [22], waist circumference density 
index [23], among others. Biological age determined by 
age-related DNA methylation has proven to be better 
than chronological age, as a predictor of 3-month 
outcomes after ischaemic stroke [24]. Biological age 
can issue a timely warning for health care and make 
people realize that his health is slipping away [12]. 
Therefore, the regular monitoring of the discrepancy 
between biological age and chronological age has 
potential positive impacts on the primary prevention 
and disease burden. 
 
Biological ageing is associated with reduced reparative 
and regenerative potential of the body [25]. The ideal 
candidates to be studied for the purpose of predicting 
biological age must be representative of the level of 
homeostatic balance in the body. Plasma peptides, such 
as hormones, cytokines and growth factors, promote 
homeostasis in many biological processes [26]. 
Additionally, some plasma peptides have been found to 
be associated with age-related diseases, including 
Alzheimer's disease, hypertension, type 2 diabetes, and 
colorectal cancer [27–31]. Furthermore, our previous 
study shows that some peptides are highly correlated 
with chronological age in a Chinese population, such as 
fragment of apolipoprotein A-I, fibrinogen alpha, 
albumin and so on [19]. In particular, the levels of 
apolipoprotein A-I and fibrinogen alpha fragment 
gradually increased between 18 and 50 years of age, 
while albumin significantly degraded in middle-aged 
individuals. In the present study, we focused on 
building a biological age model with a set of specific 
plasma peptides from a Han Chinese population. 
 
RESULTS 
 
Description of the subjects 
 
This cross-sectional study included 1890 participants of 
Han Chinese descent. The summary of demographic 
variables was shown in Table 1. The median age was  
34 years (P25 27 years, P75 45 years) in all subjects,  
34 years (27 to 45 years) in male subjects, and 36 years  
(26 to 46 years) in female subjects (Table 1). All 
anthropometric variables, except for age and age group 
variables, were significantly different between male and 
female subjects (P < 0.001). Compared with female 
participants, the male subjects had greater height, 
weight, systolic blood pressure (SBP), diastolic blood 
pressure (DBP), and body mass index (BMI). 
 
Model for predicted biological age 
 
Among 84 detected peptides with masses in the range of 
0.6-10.0 kDa, 13 identified peptides with amino acid 
sequences were used for subsequent analysis (Table 2). 
In particular, 11 peptides were selected for further 
analysis based on univariate linear regression (Table 3), 
except for fragment of complement C3 (m/z 1120.39) 
and complement C4-A (m/z 1052.53). As shown in 
Table 4, five plasma peptides, including fragments of 
apolipoprotein A-I (m/z 2883.99), fibrinogen alpha 
chain (m/z 3060.13), complement C3 (m/z 2190.59), 
complement C4-A (m/z 1898.21), and breast cancer 
type 2 susceptibility protein (m/z 1607.84), were 
identified by stepwise selection in a multivariate linear 
regression based on these 11 peptides and all 
demographic traits (BMI, SBP, DBP, age group). 
Finally, a biological age model was built based on the 
five identified plasma peptides and three demographic 
variables (Table 4). The estimated biological age can be 
calculated using the following equation (1). 
 
Biological age = 13.3 + 0.122 × BMI + 0.107 × SBP + 
21.0 × age group + (-0.014) × Apolipoprotein A-I 
fragment (m/z 2883.99) + 0.004 × Fibrinogen alpha 
chain fragment (m/z 3060.13) + 0.011 × Complement 
C3 fragment (m/z 2190.59) + (-0.005) × Complement 
C4-A fragment (m/z 1898.21) + 0.019 × Breast cancer 
type 2 susceptibility protein fragment (m/z 1607.84)(1) 
 
All samples (from 1890 Chinese Han adults) were 
randomly divided into the training set (1500 samples) and 
validation set (390 samples). This model accounted for 
72.3% of the variation in chronological age, with a 
correlation between the actual age and biological age of 
0.851 (95% confidence interval (95% CI): 0.836-0.864) 
in the training set. Furthermore, in the validation set, the 
biological age was linearly correlated with the actual age 
(correlation coefficient (r) = 0.842, 95% CI: 0.810-
0.869), and the normalized mean square error (NMSE) 
was 0.30. Visual analysis of the correlations between 
biological age and chronological age is presented in 
Figure 1. The predictive effect of the model is considered 
outstanding when the correlation curve is a straight line 
and its slope is equal to 1. The 95% CI of the fitted  
curve broadened with age, suggesting that the variation  
in biological age and heterogeneity among different 
individuals increased with actual age. Thus, plasma 
peptides can serve as potential biomarkers for
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Table 1. Characteristics of the participants. 
Parameters Total (n=1890) Males (n=1136) Females (n=754) P 
Age, year 34 (27-45) 34 (27-45) 36 (26-46) 0.512 
≤ 39  1177 (62.28%) 721 (63.47%) 456 (60.48%)  
40-59 593 (31.38%) 323 (28.43%) 270 (35.81%)  
≥ 60 120 (6.35%) 92 (8.10%) 28 (3.71%)  
Age group, %    0.148 
≤ 40 years old 1225 (63.81%) 751 (66.11%) 474 (62.86%)  
> 40 years old 665 (35.19%) 385 (33.89%) 280 (37.14%)  
Height, cm 169 (163-173) 172 (169-176) 162 (158-166) < 0.001* 
Weight, kg 67 (58-76) 73 (66-81) 57 (52-63) < 0.001* 
BMI, kg/m2 23.7 (21.2-25.9) 24.6 (22.5-26.8) 21.8 (19.9-24.1) < 0.001* 
SBP, mmHg 120 (110-130) 120 (112-130) 114 (104-124) < 0.001* 
DBP, mmHg 78 (70-82) 80 (70-86) 72 (66-80) < 0.001* 
*P < 0.05 indicating that the peptide was taken as a significant one. BMI: Body mass index; SBP: Systolic blood pressure; DBP: 
Diastolic blood pressure. 
Table 2. Characteristics of identified plasma peptide in the participants. 
Peak Amino acid sequence  Peak identity Total (n=1890) 
m/z 2044.75 K.VFDEFKPLVEEPQNLIK.Q Albumin 105.3 (40.0-160.1) 
m/z 2065.31 D.APRIKKIVQKKLAGDESAD.- Pro-Platelet basic protein 35.3 (14.2-75.1) 
m/z 2487.01 S.NSRDDGNSVFPAKASATGAGPAAAEK.R 
Hyperpolarization-activated 
cyclic nucleotide-gated 
potassium channel 1  
26.1 (16.7-42.1) 
m/z 3428.10 K.YWSQQIEESTTVVTTQSAEVGAAETTLTELR.R Keratin 18 60.4 (24.3-113.5) 
m/z 2883.99 L.LPVLESFKVSFLSALEEYTKKLNTQ.- Apolipoprotein A-I  36.4 (19.5-59.2) 
m/z 1076.14 E.GDFLAEGGGVR.G Fibrinogen alpha chain 30.2 (20.6-41.8) 
m/z 3060.13 K.SSSYSKQ(+.98)FTSSTSYNRGDSTFESKSYK.M Fibrinogen alpha chain 73.6 (33.3-135.6) 
m/z 1120.39 T.HRIHWESAS.L Complement C3 18.5 (13.1-25.7) 
m/z 2190.59 G.SPMYSIITPNILRLESEET.M Complement C3 45.7 (26.2-80.4) 
m/z 1052.53 K.SHALQLNNR.Q Complement C4-A 20.6 (13.7-29.9) 
m/z 1898.21 S.STGRNGFKSHALQLNNR.Q Complement C4-A 24.3 (14.8-56.8) 
m/z 1607.84 P.KC(+57.02)KEMQNSLN(+.98)NDK.N 
Breast cancer type 2 
susceptibility protein 
19.0 (9.97-38.8) 
m/z 2211.86 V.YRLPPLRKGEVLPLPEAN(+.98)F.P Histidine-rich glycoprotein 38.1 (20.0-80.8) 
Data were presented as median together with interquartile range. Peptide content in human plasma is measured in intensity.  
predicting biological age, and their practical application 
warrants further research. 
 
DISCUSSION 
 
Biological age is a health indicator associated with 
chronological age, senescence and disease, and it can 
reflect dynamic and alterable health status better than 
chronological age [32]. In the present study, we built a 
biological age model correlated with actual age (r = 
0.842, 95% CI: 0.810-0.869) in the validation set that 
explained 72.3% of the variation in chronological age, 
but its predictive ability still needs further verification. 
To the best of our knowledge, this study is the first 
attempt to build a biological age model based on plasma 
peptides in Han Chinese adults. 
Matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF-MS) is a key 
tool for peptide analysis of human body fluids, such as 
plasma, saliva and urine samples [26]. Based on this 
method, thirteen peptides were identified their amino 
acid sequences, and five of these peptides were used to 
construct a biological age model (fragment of 
apolipoprotein A-I (m/z 2883.99), fibrinogen alpha 
chain (m/z 3060.13), complement C3 (m/z 2190.59), 
complement C4-A (m/z 1898.21), and breast cancer 
type 2 susceptibility protein (m/z 1607.84)). Compared 
to our previous study, our study found four novel 
peptides associated with age [19]. The fragment of 
apolipoprotein A-I (m/z 2883.99) was found to be a 
biomarker of biological age in our previous study [19], 
which is consistent with our results. The level of plasma
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Table 3. Univariate linear regression analysis for each identified peptide. 
Variables Coefficient SE P 95% CI 
Albumin (m/z 2044.75) -0.005 0.002 0.012* (-0.008, -0.001) 
Pro-Platelet basic protein (m/z 2065.31) -0.008 0.005 0.100* (-0.018, 0.002) 
Hyperpolarization-activated cyclic nucleotide-gated 
potassium channel 1 (m/z 2487.01) 
0.040 0.014 0.004* (0.013, 0.067) 
Keratin 18 (m/z 3428.10) 0.014 0.005 0.002* (0.005, 0.023) 
Apolipoprotein A-I (m/z 2883.99) 0.040 0.009 < 0.001* (0.023, 0.058) 
Fibrinogen alpha chain (m/z 1076.14) -0.064 0.017 < 0.001* (-0.097, -0.030) 
Fibrinogen alpha chain (m/z 3060.13) 0.009 0.003 0.002* (0.003, 0.015) 
Complement C3 (m/z 1120.39) -0.048 0.029 0.100 (-0.105, 0.009) 
Complement C3 (m/z 2190.59) 0.011 0.005 0.034* (0.001, 0.022) 
Complement C4-A (m/z 1052.53) 0.002 0.023 0.921 (-0.042, 0.046) 
Complement C4-A (m/z 1898.21) -0.007 0.004 0.074* (-0.014, 0.001) 
Breast cancer type 2 susceptibility protein (m/z 
1607.84) 
0.015 0.009 0.072* (-0.001, 0.032) 
Histidine-rich glycoprotein (m/z 2211.86) 0.007 0.004 0.090* (-0.001, 0.016) 
*P < 0.10 indicating that the peptide was taken as a significant one. The P value of pro-platelet basic protein (m/z 2065.31) was 
0.0996 which rounded to three decimal places (0.100). Complement C3 (m/z 1120.39) and Complement C4-A (m/z 1052.53) 
were not selected for further multivariate linear regression analysis. SE: Standard error; 95% CI: 95% Confidence interval. 
 
Table 4. Multiple linear regression analysis for biological age. 
Variables Coefficient SE P 95% CI 
Constant 13.3 1.73 < 0.001* (9.9, 16.7) 
BMI 0.122 0.054 0.025* (0.016, 0.229) 
SBP 0.107 0.015 < 0.001* (0.079, 0.136) 
Age group 21.0 0.387 < 0.001* (20.2, 21.7) 
Apolipoprotein A-I (m/z 2883.99)  -0.014 0.006 0.035* (-0.026, -0.001) 
Fibrinogen alpha chain (m/z 3060.13)  0.004 0.002 0.050* (3.69 × 10-6, 7.50 × 10-3) 
Complement C3 (m/z 2190.59) 0.011 0.004 0.003* (0.004, 0.019) 
Complement C4-A (m/z 1898.21) -0.005 0.003 0.053 (-1.02 × 10-2, 5.50 × 10-5) 
Breast cancer type 2 susceptibility protein (m/z 1607.84)  0.019 0.006 0.002* (0.007, 0.031) 
*P < 0.05 indicating that the peptide was taken as a significant one. The P value of fibrinogen alpha chain (m/z 3060.13) was 
0.0498 which rounded to three decimal places (0.050). Adjusted R2 = 0.723. 
BMI: Body mass index; SBP: Systolic blood pressure; SE: Standard error; 95% CI: 95% Confidence interval. 
 
 
 
Figure 1. The correlation between chronological age and biological age. (A) The model performance based on the validation set.  
(B) The model performance presented by sex in the validation set. Dotted and solid curves were fitted to describe correlations between 
biological age and chronological age in females and males, respectively. The shade region was a pointwise 95% confidence interval. 
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apolipoprotein A-I is associated with premature 
coronary artery disease [33] and clinical progression of 
Alzheimer's disease [34]. We previously found 
fibrinogen alpha chain (m/z 1076.14) fragment is 
related to ageing [19], whereas the other fragment of 
ageing-related fibrinogen alpha chain (m/z 3060.13) 
was used to build this biological age model in our study. 
Fibrinogen play an positive role in promoting blood 
haemostasis and leukocyte function regulation in 
inflammation [35]. However, elucidating the effect of 
the level of fibrinogen alpha chain fragment (m/z 
3060.13) on ageing still requires further research. 
Complement C3 activates immune function through 
complement activation [36]. Furthermore, we also 
found that other peptides (fragment of complement C4-
A (m/z 1898.21) and breast cancer type 2 susceptibility 
protein (m/z 1607.84)) can be used in predicting 
biological age, whereas their specific mechanisms in 
ageing remain to be elucidated. 
 
According to the findings of previous studies, this 
candidate biological age model had a better age 
correlation in the validation set (r = 0.842, 95% CI: 
0.810-0.869) than telomere length (r = 0.695 (95% CI: 
0.575-0.0.815), without validation) [13], transcriptomic 
predictor (r ranged from 0.348 to 0.744 in different 
independent cohorts) [17] and IgG Fc N-glycosylation 
(r = 0.59 for the Chinese population, and r = 0.84 for 
the European population) [20, 21], but a weaker 
correlation with DNA methylation age (r = 0.96) in 
their corresponding validation cohorts covering the 
entire adult life span and different ethnic populations 
[15]. Compared to the abovementioned micro biological 
age, the two macro biological ages also showed strong 
correlations with the actual age ( r ranged from 0.85 to 
0.86 for the three-dimensional facial image-based age 
predictor and r = 0.992 for the waist circumference 
density index) [22, 23]. Therefore, composite biomarker 
predictors may have potential for biological age 
assessment. In addition, our results were consistent with 
the large heterogeneity in health state of elderly 
individuals for the variation in biological age increased 
with chronological age (95% CI widen with age) [9]. 
We defined a "age group" variable, a binary variable 
grouped by 40 years old, based on complex changes of 
different peptides in different age groups (five age 
groups 18-29, 30-39, 40-49, 50-59, ≥ 60 years) [19]. 
The "age group" variable defined 40 years old as the 
demarcation point artificially based on the balance 
between these groups. Moreover, women older than 40 
years of age will experience the transitional stage 
characterized by a transition from the reproductive to 
the non-reproductive stage [37]. Epidemiological 
studies showed a high prevalence of obesity [38], 
diabetes mellitus [39], and stroke [40] in adults older 
than 40 years.  
There are several limitations of our study that should be 
acknowledged. First, due to the limitations of 
experimental conditions, there may be bias in the 
peptide analysis because we did not control for pH, 
removal of oxygen, storage under argon and enzyme 
inhibitors of all plasma samples, though we controlled 
for storage time and temperature [41]. Second, although 
MS-based peptide analysis has been widely used, the 
detection and identification process is complicated and 
time-consuming, and the pre-treatment of plasma has a 
great influence on peptide analysis [42]. Therefore, the 
pre-treatment of plasma samples and peptide analysis 
still requires methodological advancement. Finally, 
people aged 60 years or older comprised a relatively 
low proportion of the population (6.35%), which may 
lead to selection and information bias (Table 1). This 
biological age model needs to be explored in larger and 
more representative samples, including those of a  
non-Asian ethnicity, as our study only included Chinese 
Han adults. 
 
Our finding has certain implications for ageing. This 
study is the first attempt to develop a biological age 
model based on plasma peptides in Han Chinese adults. 
Biological age based on plasma peptides may have the 
potential to indicate homeostasis abnormalities and the 
rate of ageing. Our study provided evidence for further 
research in peptide-based biological age. This evidence 
may help us to understand the underlying mechanisms 
of ageing through five age-related peptides. 
 
In conclusion, our study suggested that plasma peptide 
profiles can be used to build a biological age model. 
This candidate model involving peptides and clinical 
traits was able to account for 72.3% of the variation in 
actual age, and this biological age correlated with 
chronological age (r = 0.842, 95% CI: 0.810-0.869) in 
the validation set. However, the practical applications of 
this model in primary prevention warrant further 
investigation. 
 
MATERIALS AND METHODS 
 
Subjects 
 
This cross-sectional study recruited 1927 participants of 
Han Chinese ancestry during regular health check-ups 
at Xuanwu Hospital, Capital Medical University, 
Beijing, China. Individuals who were 18 years old or 
older were eligible. In addition, subjects with a history 
of somatic or psychiatric abnormalities in their medical 
records and those who had used medication two weeks 
prior to the study were excluded. Subjects who had a 
history of cerebral infarction, cerebral haemorrhage, 
other cerebrovascular diseases, congenital heart disease, 
acute myocardial infarction, liver disease, renal failure, 
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malignant tumour, chronic obstructive pulmonary 
disease, or rheumatoid arthritis were also excluded. In 
this study, 37 participants who had missing data for one 
or more clinical traits were subsequently excluded. 
Finally, a total of 1890 participants were included in the 
subsequent analysis. Further details of the study design, 
recruitment procedure, and physical examination were 
previously described [19]. 
 
Ethics approval  
 
Written informed consent was obtained from each 
participant, and all procedures were implemented in 
accordance with the regulations of the ethics committee 
of Capital Medical University, Beijing, China.  
 
Collection of plasma samples 
 
The plasma samples for peptide analysis were collected 
according to a standard protocol. Fresh fasting blood 
samples were collected from the cubital vein into blood 
collection tubes (containing ethylenediaminetetraacetic 
acid). The plasma was separated by centrifugation at 
3,000 rpm for 15 min and then stored at −80 °C until 
peptide analysis. The number of freeze-thaw cycles of 
all samples is basically the same during this process. 
After the plasma samples of all the participants were 
collected, peptide analysis was completed at the shortest 
possible time.  
 
Magnetic bead-based sample preparation for 
peptide analysis 
 
As in previous studies [27, 28, 43], all plasma samples 
were fractionated using weak cation exchange magnetic 
beads to gather and enrich the proteins or peptides, 
according to the instructions provided by the supplier 
(ClinProt™, Bruker Daltonics, Billerica, USA) [44, 45]. 
The samples were purified and isolated through three 
steps: binding, washing, and elution. The specific 
details of this process were published in a previous 
study [19]. Then, the resulting eluates were stored in a –
20 °C freezer until further MS analysis. 
 
Peptides profiling and processing of spectral data 
 
Peptide profiling was performed by MALDI-TOF-MS 
[28, 43]. First, the eluted samples were diluted in a 
matrix solution of α-cyano-4-hydroxycinnamic acid and 
ethanol and acetone, which was prepared daily. Then, 1 
µl of the diluted samples was pipetted onto a MALDI-
TOF-MS target (AnchorChip™, Bruker Daltonics, 
Billerica, USA) and dried at room temperature before 
analysis. Finally, MALDI-TOF-MS measurements were 
performed using the Autoflex TOF instrument (Bruker 
Daltonics, Billerica, USA). Profile spectra were 
acquired from an average of 400 laser shots per sample, 
with the defined mass range of peak intensities 
(measured as m/z) of 600–10,000 Da. 
 
Quality control was carried on before the MS analysis, 
with 11 peptides as external standards where the 
average molecular weight deviation was no more than 
100 µg/g. After testing every 8 samples, each standard 
preparation was re-calibrated. Additionally, 13 
reference samples were run as external standards. The 
system performance is considered acceptable when the 
coefficient of variability is less than 30%. All reference 
peptides and samples were prepared in the same matrix 
solution as above. All of the solutions and buffers were 
prepared using MS-grade reagents. 
 
The MALDI mass spectra of peptides were analysed 
using ClinProTools (ClinProt software version 2.0, 
Bruker Daltonics, Billerica, USA) to subtract the 
baseline, normalize the spectra (using total ion current), 
and determine the peak m/z values and intensities in the 
mass range of 600–10,000 Da. In brief, local noise 
estimates were applied to estimate the background, then 
the background was subtracted from each spectrum. 
Peptide peaks with a signal-to-noise ratio higher than 
5.0 were detected and defined. The cut-off value of the 
signal-to-noise ratio was set at 5.0 because this value 
was a good compromise between over detection and 
sensitivity. A mass shift of no more than 0.1% was 
determined for the spectra alignment. The peak area was 
used for quantitative standardization. To determine the 
peak m/z values or intensities in the target mass range, a 
± 2 Da mass accuracy for each spectrum was tolerated 
[46]. To evaluate the experimental reproducibility, 
triplicate measurements were performed to examine the 
standard deviation on the same MALDI-TOF-MS 
instrument. In our study, the standard deviation was less 
than 10%, so the reproducibility for the MALDI-TOF 
MS instrument was considered acceptable.  
 
Identification of the amino acid sequences of the 
peptides 
 
The amino acid sequences of the peptides were 
identified using the nanoliquid chromatography–
electrospray ionization–tandem mass spectrometry 
(nano-LC/ESI–MS/MS) system, which is comprised of 
an Aquity UPLC system (Waters, Milford, MA, USA) 
and an LTQ Obitrap XL mass spectrometer (Thermo 
Fisher Scientific, Bremen, Germany) equipped with a 
nano-ESI source. In brief, the peptide solution was 
loaded onto a symmetry C18 trap column 
(nanoACQUITY) (180 µm × 20 mm × 5 µm) and then 
analysed by symmetry C18 analytical column 
(nanoACQUITY, Waters, Milford, MA, USA) (75 µm 
× 150 mm × 3.5 µm). The mobile phases A, mobile 
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phases B, flow rate and gradient elution were operated 
according to the published paper [19]. The running 
mode of the MS instrument was operated in a data-
dependent model. The range of the full scan was 400–
2,000 m/z with a mass resolution of 100,000 at m/z 400. 
The FDR cut-off value was set to 0.01 during the whole 
identification process. The eight strongest monoisotopic 
ions were the precursors for collision-induced 
dissociation. The MS/MS spectra were restricted to two 
consecutive scans per precursor ion followed by a 60-
sec of dynamic exclusion.  
 
To identify the peptides, the chromatograms were 
analysed using BioWorksBrowserTM 3.3.1 SP1 software 
(Thermo Fisher Scientific, Bremen, Germany). The 
resulting mass lists were located on the Sequest™ (IPI 
Human v3.45) database (Thermo Scientific, Waltham, 
MA, USA). Due to the generation of the peak list, the 
parent ion and fragment mass relative accuracy were set 
at 50 µg/g and 1 Da, respectively. MS/MS product-ion 
mass spectra were presented in Figure 2. 
 
Measurements 
 
The dataset consisted of 7 main demographic variables: 
age (years), gender, height (cm), weight (kg), BMI 
(kg/m2), SBP (mmHg), DBP (mmHg). Considering that 
participants at different ages might have large variation 
in physiological functions [37–40], the constructed 
model included a “age group” variable defined by a 
binary indicator, where people aged 40 years and below 
were represented as 1, and people aged above 40 years 
were represented as 2. In addition, 84 peptides were 
detected, with masses in the range of 0.6-10.0 kDa. 
Among these peptides, 13 peptides were successfully 
identified as known amino acid sequences. These 
demographic variables above and the 13 identified 
peptides were used for subsequent analysis. 
 
Statistical analysis 
 
Continuous variables were expressed as median and 
interquartile ranges. Frequencies and percentages were 
used to express the categorical variables. Continuous 
variables in the two gender groups were compared using 
the Mann-Whitney U test. The χ2 test was used to 
compare proportions for categorical variables. 
Multivariate linear regression was used for the 
biological age model. The samples were randomly 
divided into the training set (1500 samples) and 
validation set (390 samples). The training set and the 
independent validation set were used for modelling and 
model validation, respectively. First, a univariate linear 
regression model was implemented for preliminary 
selection. If the peptide had a P value lower than the 
entering threshold (P < 0.10), then the peptide could be
 
 
 
Figure 2. The total ion current chromatograms of secondary ion mass spectrometry. 
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used for further variable screening. Second, all candidate 
peptides were entered in a multivariate linear regression 
with stepwise selection adjusting for all demographic 
variables. The direction argument and entering threshold 
of stepwise regression were set to “both” and “0.10”, 
respectively. The criteria for variable selection were 
based on the Akaike information criterion. Finally, 
variables identified by stepwise selection were used to 
build the final biological age mode. The performance of 
this biological age model was evaluated by the 
coefficient of determination (R2) and NMSE of 
prediction errors in the independent validation set. Except 
for variable screening of peptides in regression analysis, a 
two-tailed P-value < 0.05 was considered statistically 
significant. All statistical analyses were performed using 
R version 3.3.3 (R Foundation for Statistical Computing, 
Vienna, Austria). 
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